Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company StockDefense World · 6 days ago
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekZacks Investment Research · Oct 15, 2026
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Zacks Investment Research · Oct 14, 2026
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 MillionGlobeNewsWire · Oct 14, 2026
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)Defense World · Oct 14, 2026
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)Defense World · Oct 12, 2026Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$1.22 | -$0.90 | Beat |
| May 5, 2026 | -$1.49 | -$1.84 | Miss |
| Feb 12, 2026 | -$1.20 | -$1.29 | Miss |
| Nov 4, 2025 | -$1.23 | -$1.81 | Miss |
| Aug 5, 2025 | -$1.27 | -$1.17 | Beat |
| May 6, 2025 | -$1.54 | -$1.57 | Miss |